Indeed, many ADAM17-selective inhibitors used in experimental protocols have shown a lack of efficacy in Phase II clinical trials, as in RA patients’ treatment; currently, no molecule has passed the various evaluation phases in clinical trials, and, therefore, there are no drugs available on the market. This evidence concerns the gene ADAM17 and rheumatoid arthritis.